NurExone Touts Nano-Therapy as Key Executive Departs

TORONTO and HAIFA, Israel – February 27, 2026 – NurExone Biologic Inc. is preparing for a pivotal month, poised to showcase its exosome-based regenerative medicine platform at two major international conferences. However, the announcement of this strategic scientific and commercial push was simultaneously delivered with news of a significant executive departure, creating a complex narrative of forward momentum and internal transition for the biopharmaceutical company.

A Two-Pronged Push on the Global Stage

In March, NurExone will engage in a strategic outreach campaign, presenting its technology to both the scientific and commercial sectors of the advanced therapies industry. This dual approach underscores the company's phase of development, bridging cutting-edge science with the practicalities of bringing a therapy to market.

First, the company will participate in NANO.IL.2026 in Jerusalem, an international hub for nanoscience and nanotechnology. The relevance is profound, as NurExone's entire platform is built upon exosomes—nanoscale vesicles that act as cellular messengers. CEO Dr. Lior Shaltiel is slated not only as an invited speaker but also as a co-chair for a session on industrial approaches in nanobiotechnology. This role places NurExone at the heart of the foundational science that powers its therapeutic candidates.

Shortly after, Dr. Shaltiel will travel to London for the Advanced Therapies Congress, Europe's largest commercial gathering for the cell and gene therapy industry. Here, the focus shifts from pure science to application and commercialization. The congress is a critical venue for addressing challenges in clinical translation, manufacturing scalability, and investment. Dr. Shaltiel’s presentation, titled "From start-up to a publicly traded company," is aimed squarely at the business and investment communities, highlighting the company's journey and future commercial strategy.

In the company's press release, Dr. Shaltiel framed the dual appearances as representing “two sides of the same innovation pathway - one focused on nano scale biology and delivery technologies, and the other on what it takes to translate them into a therapy built for consistent manufacturing, regulatory and clinical progress.”

The Science and Strategy Behind ExoPTEN

At the core of NurExone's ambition is its lead product, ExoPTEN. This therapy is being developed for devastating central nervous system (CNS) conditions, specifically acute spinal cord injury and optic nerve injury—both multi-billion-dollar markets with immense unmet medical needs. The therapy utilizes exosomes loaded with a therapeutic cargo designed to promote regeneration and recovery.

A significant tailwind for the company is the Orphan Drug Designation (ODD) it has secured for ExoPTEN. This designation, granted by regulators like the FDA and EMA, is reserved for therapies targeting rare diseases or conditions. It provides substantial incentives, including a period of market exclusivity post-approval (typically seven years in the U.S. and ten in Europe), tax credits for clinical trials, and streamlined regulatory guidance. For a company like NurExone, the ODD is a critical asset that de-risks the development path and enhances the commercial attractiveness of its lead candidate.

Furthermore, the company has recently made strides in an area that often proves to be the Achilles' heel for advanced therapy companies: manufacturing. In early February, NurExone announced it had validated a scalable and potent manufacturing platform, demonstrating independent batch consistency. Achieving consistent, high-quality production of exosomes at scale is a crucial bioengineering milestone required for clinical trials and eventual commercial supply, positioning the company favorably within a competitive landscape.

Navigating an Unexpected Leadership Transition

While the company prepares its external showcase, it is also managing a significant internal change. The same announcement revealed that Mr. Jacob Licht will be stepping down from his roles as Vice President of Corporate Development at NurExone and as Chief Executive Officer of its U.S. subsidiary, Exo-Top Inc., at the end of March for personal reasons.

This is no minor shuffle. Mr. Licht's roles placed him at the nexus of NurExone's growth strategy, particularly in North America. Exo-Top Inc. was established as a strategic pillar to anchor the company's U.S. activities and to commercialize its platform by offering quality exosomes and delivery systems to other drug developers. His departure creates a leadership vacuum in corporate development and for the subsidiary tasked with executing a key part of the company's long-term business model.

NurExone has stated that its existing management team will assume Mr. Licht's responsibilities in the interim. The company's forward-looking statements acknowledge the need to “maintain continuity” through these measures. However, the departure of the executive specifically charged with building out the U.S. subsidiary and corporate partnerships introduces a degree of uncertainty. The effectiveness of the interim plan and the speed at which a permanent solution is found will be critical in maintaining momentum on these strategic fronts.

Balancing Promise with Pragmatism

For investors tracking NurExone on the TSX Venture Exchange, OTCQB, or Frankfurt Stock Exchange, the latest developments present a dual-sided picture. The company, with a market capitalization of approximately C$46.87 million, is making all the right moves toward the clinic. It is building on strong preclinical data, securing valuable regulatory designations, solving complex manufacturing challenges, and actively engaging with the global scientific and investment communities.

The planned initiation of "first-in-human" clinical trials for ExoPTEN in 2026 remains the company's most significant upcoming catalyst. Each step toward that goal, from manufacturing validation to conference presentations, is designed to build confidence and reduce perceived risk. Yet, the path of a clinical-stage biotech is rarely without its challenges. The departure of a key executive adds an operational and strategic hurdle that the company must now navigate effectively. For investors and patients alike, the company's ability to execute on its scientific promise while managing this executive transition will be the defining story of 2026.